Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050000, China.
Biomed Res Int. 2023 Jan 19;2023:7443226. doi: 10.1155/2023/7443226. eCollection 2023.
Ciprofol is a novel compound that was independently developed in China. According to the Chinese product instructions approved by the China National Medical Products Administration and the information of official website, indications for ciprofol include sedation and anesthesia during the surgical/procedure of nontracheal intubation, induction and maintenance of general anesthesia, and sedation during intensive care. Ciprofol is a short-acting intravenous sedative based on the structural modification of propofol. Ciprofol has high efficacy, good selectivity, and fewer adverse reactions, indicating good clinical application potential. A series of clinical studies have been conducted to evaluate the sedative effect of ciprofol in various procedures and settings, including gastroscopy and colonoscopy, fiber-optic bronchoscopy, general anesthesia in elective surgeries, and mechanical ventilation in intensive care units. This review summarizes the chemical structure, pharmacodynamics, and pharmacokinetic properties of ciprofol. We also assessed the efficacy and safety of ciprofol by synthesizing the relevant clinical trial data.
西普罗夫是一种新型化合物，由中国自主研发。根据中国国家药品监督管理局批准的中文产品说明书和官方网站信息，西普罗夫的适应证包括非气管插管手术/程序中的镇静和麻醉、诱导和维持全身麻醉以及重症监护期间的镇静。西普罗夫是一种基于丙泊酚结构修饰的短效静脉镇静剂。西普罗夫具有高效、选择性好、不良反应少的特点，显示出良好的临床应用潜力。已经进行了一系列临床研究来评估西普罗夫在各种程序和环境中的镇静效果，包括胃镜和结肠镜检查、纤维支气管镜检查、择期手术中的全身麻醉以及重症监护病房中的机械通气。本综述总结了西普罗夫的化学结构、药效学和药代动力学特性。我们还通过综合相关临床试验数据来评估西普罗夫的疗效和安全性。
